US20030091549A1 - Probiotic lactobacillus salivarius strains - Google Patents

Probiotic lactobacillus salivarius strains Download PDF

Info

Publication number
US20030091549A1
US20030091549A1 US10/205,318 US20531802A US2003091549A1 US 20030091549 A1 US20030091549 A1 US 20030091549A1 US 20531802 A US20531802 A US 20531802A US 2003091549 A1 US2003091549 A1 US 2003091549A1
Authority
US
United States
Prior art keywords
lactobacillus salivarius
strain
formulation
strains
lactobacillus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/205,318
Other languages
English (en)
Inventor
John Collins
Gerald O'Sullivan
Liam O'Mahony
Fergus Shanahan
Barry Kiely
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PrecisionBiotics Group Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to ALIMENTARY HEALTH LIMITED reassignment ALIMENTARY HEALTH LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COLLINS, JOHN KEVIN, KIELY, BARRY, O'MAHONY, LIAM, O'SULLIVAN, GERALD CHRISTOPHER, SHANAHAN, FERGUS
Publication of US20030091549A1 publication Critical patent/US20030091549A1/en
Priority to US11/105,590 priority Critical patent/US7390519B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/181—Salivarius
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Definitions

  • the invention relates to Lactobacillus salivarius strains and their use as probiotic bacteria in particular as immunomodulatory biotherapeutic agents.
  • the defense mechanisms to protect the human gastrointestinal tract from colonization by intestinal bacteria are highly complex and involve both immunological and non-immunological aspects (1).
  • Innate defense mechanisms include the low pH of the stomach, bile salts, peristalsis, mucin layers and anti-microbial compounds such as lysozyme (2).
  • Immunological mechanisms include specialized lymphoid aggregates, underlying M cells, called peyers patches which are distributed throughout the small intestine and colon (3). Luminal antigens presented at these sites result in stimulation of appropriate T and B cell subsets with establishment of cytokine networks and secretion of antibodies into the gastrointestinal tract (4).
  • antigen presentation may occur via epithelial cells to intraepithelial lymphocytes and to the underlying lamina limba immune cells (5). Therefore, the host invests substantially in immunological defense of the gastrointestinal tract.
  • the gastrointestinal mucosa is the largest surface at which the host interacts with the external environment, specific control mechanisms must be in place to regulate immune responsiveness to the 100 tons of food which is handled by the gastrointestinal tract over an average lifetime.
  • the gut is colonized by over 500 species of bacteria numbering 10 11 -10 12 /g in the colon.
  • these control mechanisms must be capable of distinguishing non-pathogenic adherent bacteria from invasive pathogens, which would cause significant damage to the host.
  • the intestinal flora contributes to defense of the host by competing with newly ingested potentially pathogenic micro-organisms.
  • Bacteria present in the human gastrointestinal tract can promote inflammation. Aberrant immune responses to the indigenous microflora have been implicated in certain disease states, such as inflammatory bowel disease. Antigens associated with the normal flora usually lead to immunological tolerance and failure to achieve this tolerance is a major mechanism of mucosal inflammation (6). Evidence for this breakdown in tolerance includes an increase in antibody levels directed against the gut flora in patients with IBD.
  • the present invention is directed towards Lactobacillus strains, which have been shown to have immunomodulatory effects, by modulating cytokine levels or by antagonizing and excluding pro-inflammatory micro-organisms from the gastrointestinal tract.
  • a Lactobacillus salivarius strain selected from any one or more of AH102, AH103, AH105, AH109 and AH110 or a mutant or variant thereof.
  • the mutant may be a genetically modified mutant.
  • the variant may be a naturally occurring variant of Lactobacillus salivarius.
  • Lactobacillus salivarius strains are in the form of viable cells.
  • Lactobacillus salivarius strains are in the form of non-viable cells.
  • the strains are in the form of a biologically pure culture.
  • the Lactobacillus salivarius strains are isolated from resected and washed human gastrointestinal tract.
  • the Lactobacillus salivarius strains are significantly immunomodulatory following oral consumption in humans.
  • the invention also provides a formulation which comprises at least one Lactobacillus salivarius strain of the invention.
  • the formulation may comprise two or more strains of Lactobacillus.
  • the formulation includes another probiotic material.
  • the formulation includes a prebiotic material.
  • the formulation includes an ingestable carrier.
  • the ingestable carrier may be a pharmaceutically acceptable carrier such as a capsule, tablet or powder.
  • the ingestable carrier is a food product such as acidified milk, yoghurt, frozen yoghurt, milk powder, milk concentrate, cheese spreads, dressings or beverages.
  • the formulation of the invention further comprises a protein and/or peptide, in particular proteins and/or peptides that are rich in glutamine/glutamate, a lipid, a carbohydrate, a vitamin, mineral and/or trace element.
  • Lactobacillus salivarius strains are present in the formulation at more than 10 6 cfu per gram of delivery system.
  • the formulation includes any one or more of an adjuvant, a bacterial component, a drug entity or a biological compound.
  • the formulation is for immunisation and vaccination protocols.
  • the invention further provides Lactobacillus salivarius strains or a formulation of the invention for use as foodstuffs, as a medicament, for use in the prophylaxis and/or treatment of undesirable inflammatory activity, for use in the prophylaxis and/or treatment of undesirable gastrointestinal inflammatory activity such as inflammatory bowel disease such as Crohns disease or ulcerative colitis, irritable bowel syndrome, pouchitis, or post infection colitis, for use in the prophylaxis and/or treatment of gastrointestinal cancer(s), for use in the prophylaxis and/or treatment of systemic disease such as rheumatoid arthritis, for use in the prophylaxis and/or treatment of autoimmune disorders due to undesirable inflammatory activity, for use in the prophylaxis and/or treatment of cancer due to undesirable inflammatory activity, for use in the prophylaxis of cancer, for use in the prophylaxis and/or treatment of diarrhoeal disease due to undesirable inflammatory activity, such as Clostridium difficile
  • the invention also provides Lactobacillus salivarius strains or a formulation of the invention for use in the preparation of an anti-inflammatory biotherapeutic agent for the prophylaxis and/or treatment of undesirable inflammatory activity or for use in the preparation of anti-inflammatory biotherapeutic agents for the prophylaxis and/or treatment of undesirable inflammatory activity.
  • the strains of the invention act by antagonising and excluding proinflammatory micro-organisms from the gastrointestinal tract.
  • the invention also provides Lactobacillus salivarius strains or a formulation of the invention for use in the preparation of anti-inflammatory biotherapeutic agents for reducing the levels of pro inflammatory cytokines such as IL8.
  • the invention further provides Lactobacillus salivarius strains for use in the preparation of anti-inflammatory biotherapeutic agents for modulating cytokine levels such as IL-8, IL-10, IL-12, TNF ⁇ or IFN ⁇ .
  • the invention further provides Lactobacillus salivarius strains for use in the preparation of biotherapeutic agents for modifying the levels of IFN ⁇ .
  • the strains are selected from any one of AH102, AH103 or AH105.
  • the invention further provides Lactobacillus salivarius strains for use in the preparation of biotherapeutic agents for modifying the levels of IL-10.
  • the invention further provides Lactobacillus salivarius strains for use in the preparation of biotherapeutic agents for modifying the levels of IL-12.
  • the invention further provides Lactobacillus salivarius strains for use in the preparation of biotherapeutic agents for modifying the levels of IL-8.
  • the invention further provides Lactobacillus salivarius AH110 for use in the preparation of biotherapeutic agents for modifying the levels of TNF ⁇ .
  • the invention also provides for the use of Lactobacillus salivarius strains as antiinfective probiotic strains due to their ability to antagonise the growth of pathogenic species.
  • the invention is therefore of major potential therapeutic value in the prophylaxis or treatment of dysregulated immune responses, such as undesirable inflammatory reactions, for example inflammatory bowel disease.
  • the strains may be used as a panel of biotherapeutic agents from which a selection can be made for modifying the levels of IFN ⁇ , TNF ⁇ , IL-8, IL-10 and/or IL-12.
  • the strains or formulations of the invention may be used in the prevention and/or treatment of inflammatory disorders, immunodeficiency, inflammatory bowel disease, irritable bowel syndrome, cancer (particularly of the gastrointestinal and immune systems), diarrhoeal disease, antibiotic associated diarrhoea, paediatric diarrhoea, appendicitis, autoimmune disorders, multiple sclerosis, Alzheimer's disease, rheumatoid arthritis, coeliac disease, diabetes mellitus, organ transplantation, bacterial infections, viral infections, fungal infections, periodontal disease, urogenital disease, sexually transmitted disease, HIV infection, HIV replication, HIV associated diarrhoea, surgical associated trauma, surgical-induced metastatic disease, sepsis, weight loss, anorexia, fever control, cachexia, wound healing, ulcers, gut barrier function, allergy, asthma, respiratory disorders, circulatory disorders, coronary heart disease, anaemia, disorders of the blood coagulation system, renal disease, disorders of the central nervous system,
  • Lactobacillus strains are commensal microorganisms. They have been isolated from the microbial flora within the human gastrointestinal tract. The immune system within the gastrointestinal tract cannot have a pronounced reaction to members of this flora, as the resulting inflammatory activity would also destroy host cells and tissue function.
  • a deposit of Lactobacillus salivarius strain AH102 was made at the National Collections of Industrial and Marine Bacteria Limited (NCIMB) on Apr. 20, 2000 and accorded the accession number NCIMB 41044.
  • a deposit of Lactobacillus salivarius strain AH103 was made at the NCIMB on Apr. 20, 2000 and accorded the accession number NCIMB 41045.
  • Lactobacillus salivarius strain AH105 was made at the NCIMB on Apr. 20, 2000 and accorded the accession number NCIMB 41047.
  • Lactobacillus salivarius strain AH110 was made at the NCIMB on Mar. 22, 2001 and accorded the accession number NCIMB 41094.
  • the Lactobacillus salivarius may be a genetically modified mutant or it may be a naturally occurring variant thereof.
  • the Lactobacillus salivarius is in the form of viable cells.
  • the Lactobacillus salivarius may be in the form of non-viable cells.
  • Lactobacillus strain of the invention may be administered to animals (including humans) in an orally ingestible form in a conventional preparation such as capsules, microcapsules, tablets, granules, powder, troches, pills, suppositories, suspensions and syrups.
  • a conventional preparation such as capsules, microcapsules, tablets, granules, powder, troches, pills, suppositories, suspensions and syrups.
  • Suitable formulations may be prepared by methods commonly employed using conventional organic and inorganic additives.
  • the amount of active ingredient in the medical composition may be at a level that will exercise the desired therapeutic effect.
  • the formulation may also include a bacterial component, a drug entity or a biological compound.
  • a vaccine comprising any one or more of the strains of the invention may be prepared using any suitable known method and may include a pharmaceutically acceptable carrier or adjuvant.
  • mutant, variant and genetically modified mutant include a strain of Lactobacillus salivarius whose genetic and/or phenotypic properties are altered compared to the parent strain.
  • Naturally occurring variant of Lactobacillus salivarius includes the spontaneous alterations of targeted properties selectively isolated while deliberate alteration of parent strain properties may be accomplished by conventional genetic manipulation technologies, such as gene disruption, conjugative transfer, etc.
  • FIG. 1 is a bar graph showing the number of adherent bacteria per 20 epithelial cells using human gastrointestinal epithelial cells, CaCo-2 and HT-29;
  • FIG. 2 is a bar graph showing IFN ⁇ levels induced by PBMCs following co-incubation with Lactobacillus salivarius strains;
  • FIG. 3 is a bar graph showing the effect on the levels of IL-10 (pg/ml) induced by PBMCs following co-incubation with Lactobacillus salivarius strains;
  • FIG. 4 is a bar graph showing the effect of Lactobacillus salivarius strains on PBMC IL-12 (pg/ml) production;
  • FIG. 5 is a bar graph showing the effect of Lactobacillus salivarius strains on PBMC IL-8 (pg/ml) production.
  • FIG. 6 is a bar graph showing the ability of Lactobacillus salivarius strains to modulate proinflammatory cytokine production measured in pg/ml.
  • Lactobacillus salivarius strains AH102, AH103, AH105, AH109 and AH110 are not only acid and bile tolerant and adhere to human intestinal cell lines but also, surprisingly have immunomodulatory effects, by modulating cytokine levels or by antagonising and excluding pro-inflammatory or immunomodulatory micro-organisms from the gastrointestinal tract.
  • probiotic bacteria in the form of viable cells.
  • non-viable cells such as killed cultures or compositions containing beneficial factors expressed by the probiotic bacteria. This could include thermally killed micro-organisms or micro-organisms killed by exposure to altered pH or subjection to pressure.
  • non-viable cells product preparation is simpler, cells may be incorporated easily into pharmaceuticals and storage requirements are much less limited than viable cells.
  • Lactobacillus casei YIT 9018 offers an example of the effective use of heat killed cells as a method for the treatment and/or prevention of tumour growth as described in U.S. Pat. No. 4,347,240.
  • LPS lipopolysaccharide
  • Interleukin-8 is one of the cytokines comprising the Macrophage Inflammatory protein family (MIP).
  • MIP-1 and -2 families represent a group of proteins which are chemotactic factors for leukocytes and fibroblasts. This family of proteins are also called intercrines, as cells other than macrophages are capable of synthesizing them. These cells include T and B cells, fibroblasts, endothelial cells, keratinocytes, smooth muscle cells, synovial cells, neutrophils, chondrocytes, hepatocytes, platelets and tumour cells.
  • MIP-1 ⁇ , -1 ⁇ , connective tissue activating protein (CTAP), platelet factor 4 (PF4) and IL-8 stimulate neutrophil chemotaxis.
  • Monocyte chemotactic protein (MCP-1) and RANTES are chemotactic for monocytes, IL-8 for neutrophils and lymphocytes while PF4 and CTAP are chemotactic for fibroblasts. Roles other than chemotaxis have been described for some of these family members.
  • MCP-1 stimulates monocyte cytostatic activity and superoxide anion release.
  • CTAP and PF4 increase fibroblast proliferation
  • IL-8 increases vascular permeability while MIP-1 ⁇ and -1 ⁇ are pyrogenic.
  • IL-8 is intimately involved in inflammatory responses within the gastrointestinal tract. Stimulation of IL-8 (and other proinflammatory cytokines) could contribute to the development of gastrointestinal lesions therefore it is important that probiotic bacteria should not stimulate the production of this cytokine.
  • IL-10 is produced by T cells, B cells, monocytes and macrophages. This cytokine augments the proliferation and differentiation of B cells into antibody secreting cells. IL-10 exhibits mostly anti-inflammatory activities. It up-regulates IL-1RA expression by monocytes and suppresses the majority of monocyte inflammatory activities. IL-10 inhibits monocyte production of cytokines, reactive oxygen and nitrogen intermediates, MHC class II expression, parasite killing and IL-10 production via a feed back mechanism (7). This cytokine has also been shown to block monocyte production of intestinal collagenase and type IV collagenase by interfering with a PGE 2 -cAMP dependant pathway and therefore may be an important regulator of the connective tissue destruction seen in chronic inflammatory diseases.
  • IL-12 is a heterodimeric protein of 70 kD composed of two covalently linked chains of 35 kD and 40 kD. It is produced primarily by antigen presenting cells, such as macrophages, early in the inflammatory cascade. Intracellular bacteria stimulate the production of high levels of IL-12. It is a potent inducer of IFN ⁇ production and activator of natural killer cells.
  • IL-12 is one of the key cytokines necessary for the generation of cell mediated, or Th1, immune responses primarily through its ability to prime cells for high IFN ⁇ production (8). IL-12 induces the production of IL-10 which feedback inhibits IL-12 production thus restricting uncontrolled cytokine production. TGF- ⁇ also down-regulates IL-12 production.
  • IL-4 and IL-13 can have stimulatory or inhibitory effects on IL-12 production. Inhibition of IL-12 in vivo may have some therapeutic value in the treatment of Th1 associated inflammatory disorders, such as multiple sclerosis (9).
  • Interferon-gamma is primarily a product of activated T lymphocytes and due to variable glycosylation it can be found ranging from 20 to 25 kDa in size. This cytokine synergizes with other cytokines resulting in a more potent stimulation of monocytes, macrophages, neutrophils and endothelial cells. IFN ⁇ also amplifies lipopolysaccharide (LPS) induction of monocytes and macrophages by increasing cytokine production (10), increased reactive intermediate release, phagocytosis and cytotoxicity.
  • LPS lipopolysaccharide
  • IFN ⁇ induces, or enhances the expression of major histocompatibility complex class II (MHC class II) antigens on monocytic cells and cells of epithelial, endothelial and connective tissue origin. This allows for greater presentation of antigen to the immune system from cells within inflamed tissues.
  • IFN ⁇ may also have anti-inflammatory effects. This cytokine inhibits phospholipase A 2 , thereby decreasing monocyte production of PGE 2 and collagenase (11). IFN ⁇ may also modulate monocyte and macrophage receptor expression for TGF ⁇ , TNF ⁇ and C5a (11) thereby contributing to the anti-inflammatory nature of this cytokine. Probiotic stimulation of this cytokine would have variable effects in vivo depending on the current inflammatory state of the host, stimulation of other cytokines and the route of administration.
  • MHC class II major histocompatibility complex class II
  • TNF ⁇ is a proinflammatory cytokine which mediates many of the local and systemic effects seen during an inflammatory response.
  • This cytokine is primarily a monocyte or macrophage derived product but other cell types including lymphocytes, neutrophils, NK cells, mast cells, astrocytes, epithelial cells endothelial cells and smooth muscle cells can also synthesise TNF ⁇ .
  • TNF ⁇ is synthesised as a prohormone and following processing the mature 17.5 kDa species can be observed.
  • Purified TNF ⁇ has been observed as dimers, trimers and pentamers with the trimeric form postulated to be the active form in vivo. Three receptors have been identified for TNF ⁇ .
  • TNF ⁇ inhibitor (12) A soluble receptor seems to function as a TNF ⁇ inhibitor (12) while two membrane bound forms have been identified with molecular sizes of 60 and 80 kDa respectively.
  • Local TNF ⁇ production at inflammatory sites can be induced with endotoxin and the glucocorticoid dexamethasone inhibits cytokine production (13).
  • TNF ⁇ production results in the stimulation of many cell types.
  • Significant anti-viral effects could be observed in TNF ⁇ treated cell lines (14) and the IFNs synergise with TNF ⁇ enhancing this effect.
  • Endothelial cells are stimulated to produce procoagulant activity, expression of adhesion molecules, IL-1, hematopoitic growth factors, platelet activating factor (PAF) and arachidonic acid metabolites.
  • PAF platelet activating factor
  • TNF ⁇ stimulates neutrophil adherence, phagocytosis, degranulation (15), reactive oxygen intermediate production and may influence cellular migration.
  • Leucocyte synthesis of GM-CSF, TGF ⁇ , IL-1, IL-6, PGE 2 and TNF ⁇ itself can all be stimulated upon TNF ⁇ administration (16, 17).
  • Programmed cell death (apoptosis) can be delayed in monocytes (18) while effects on fibroblasts include the promotion of chemotaxis and IL-6, PGE 2 and collagenase synthesis. While local TNF ⁇ production promotes wound healing and immune responses, the dis-regulated systemic release of TNF ⁇ can be severely toxic with effects such as cachexia, fever and acute phase protein production being observed (19).
  • Frozen tissues were thawed, weighed and placed in cysteinated (0.05%) one quarter strength Ringers' solution. The sample was gently shaken to remove loosely adhering microorganisms (termed—wash ‘W’). Following transfer to a second volume of Ringer's solution, the sample was vortexed for 7 mins to remove tightly adhering bacteria (termed—sample ‘S’). In order to isolate tissue embedded bacteria, samples 356, 176 and A were also homogenized in a Braun blender (termed—homogenate ‘H’).
  • the solutions were serially diluted and spread-plated (100 ⁇ l) on the following agar media: RCM (reinforced clostridia media) and RCM adjusted to pH 5.5 using acetic acid; TPY (trypticase, peptone and yeast extract); MRS (deMann, Rogosa and Sharpe); ROG (acetate medium (SL) of Rogosa); LLA (liver-lactose agar of Lapiere); BHI (brain heart infusion agar); LBS (Lactobacillus selective agar) and TSAYE (tryptone soya sugar supplemented with 0.6% yeast extract). TPY and MRS supplemented with propionic acid was also used.
  • agar media was supplied by Oxoid Chemicals with the exception of TPY agar. Plates were incubated in anaerobic jars (BBL, Oxoid) using CO 2 generating kits (Anaerocult A, Merck) for 2-5 days at 37° C.
  • Gram positive, catalase negative rod-shaped or bifurcated/pleomorphic bacteria isolates were streaked for purity on to complex non-selective media (MRS and TPY). Isolates were routinely cultivated in MRS or TPY medium unless otherwise stated at 37° C. under anaerobic conditions. Presumptive Lactobacillus were stocked in 40% glycerol and stored at ⁇ 20° C. and ⁇ 80° C.
  • Biochemical and physiological traits of the bacterial isolates were determined to aid identification. Nitrate reduction, indole formation and expression of ⁇ -galactosidase activity were assayed. Growth at both 15° C. and 45° C., growth in the presence of increasing concentrations of NaCl up to 5.0% and protease activity on gelatin were determined. Growth characteristics of the strains in litmus milk were also assessed.
  • the API 50CHL (BioMerieux SA, France) system was used to tentatively identify the Lactobacillus species by their carbohydrate fermentation profiles. Overnight MRS cultures were harvested by centrifugation and resuspended in the suspension medium provided with the kit. API strips were inoculated and analysed (after 24 and 48 h) according to the manufacturers' instructions. Identity of the Lactobacillus sp. was then checked by SDS-Polyacrylamide gel electrophoresis analysis (SDS-PAGE) of total cell protein (Bruno Pot, University of Ghent, Belgium, personal communication). Finally, 16s RNA analysis and ribotyping were used to confirm strain identity.
  • SDS-PAGE SDS-Polyacrylamide gel electrophoresis analysis
  • the API 50CHL allowed rapid identification of the Lactobacillus isolates. Analysis of total cell protein of the Lactobacillus sp. (Bruno Pot, personal communication) by SDS-PAGE, 16s RNA analysis and ribotyping revealed further information on the specific species. Table 3 below shows the identification of the 5 Lactobacillus strains by four different techniques. TABLE 3 Sugar fermentation Total cell protein 16s RNA Strain profiles (SDS-PAGE)* identification Ribotyping AH102 L. salivarius L. salivarius L. salivarius L. salivarius subsp. salivarius subsp. salicinius AH103 L. salivarius L. salivarius L. salivarius subsp. salivarius subsp. salicinius AH105 L.
  • the API ZYM system (BioMerieux, France) was used for semi-quantitative measurement of constitutive enzymes produced by Lactobacillus isolates.
  • Bacterial cells from the late logarithmic growth phase were harvested by centrifugation at 14,000 g for 10 mins. The pelleted cells were washed and resuspended in 50 mM phosphate buffer, pH 6.8 to the same optical density. The strips were inoculated in accordance with the manufacturer's instructions, incubated for 4 h at 37° C. and colour development recorded.
  • Antibiotic sensitivity profiles of the isolates were determined using the ‘disc susceptibility’ assay. Cultures were grown up in the appropriate broth medium for 24-48 h spread-plated (100 ⁇ l) onto agar media and discs containing known concentrations of the antibiotics were placed onto the agar. Strains were examined for antibiotic sensitivity after 1-2 days incubation at 37° C. under anaerobic conditions. Strains were considered sensitive if zones of inhibition of 1 mm or greater were seen.
  • Human gastric juice was obtained from healthy subjects by aspiration through a nasogastric tube (Mercy Hospital, Cork, Ireland). It was immediately centrifuged at 13,000 g for 30 min to remove all solid particles, sterilised through 0.45 ⁇ m and 0.2 ⁇ m filters and divided into 40 ml aliquots which were stored at 4° C. and ⁇ 20° C.
  • Pepsin activity was measured using the quantitative haemoglobulin assay. Briefly, aliquots of gastric juice (1 ml) were added to 5 ml of substrate (0.7 M urea, 0.4% (w/v) bovine haemoglobulin (Sigma Chemical Co., 0.25 M KCl-HCl buffer, pH 2.0) and incubated at 25° C. Samples were removed at 0, 2, 4, 6, 8, 10, 20 and 30 min intervals. Reactions were terminated by the addition of 5% trichloracetic acid (TCA) and allowed to stand for 30 min without agitation. Assay mixtures were then filtered (Whatman, no.
  • TCA 5% trichloracetic acid
  • pepsin enzyme activity was defined as the amount of enzyme required to cause an increase of 0.001 units of A 280 nm per minute at pH 2.0 measured as TCA-soluble products using haemoglobulin as substrate.
  • Lactobacillus strains were propagated in buffered MRS broth (pH 6.0) daily for a 5 day period. The cells were harvested, washed and resuspended in pH adjusted MRS broth and survival measured over a 2 h period using the plate count method.
  • Each of the strains was generally resistant to pH values 3.5, 3.0, and 2.5, with Lactobacillus salivarius AH102 and AH105 also exhibiting resistance at pH 2.0 (data not shown).
  • Bile samples isolated from several human gall-bladders, were stored at ⁇ 80° C. before use. For experimental work, bile samples were thawed, pooled and sterilised at 80° C. for 10 min. Bile acid composition of human bile was determined using reverse-phase High Performance Liquid Chromatography (HPLC) in combination with a pulsed amperometric detector according to the method of Dekker et al. (20). Human bile was added to MRS/TPY agar medium at a concentration of 0.3% (v/v). Freshly streaked cultures were examined for growth after 24 and 48 h.
  • HPLC High Performance Liquid Chromatography
  • Plate assay All the cultures were streaked on MRS agar plates supplemented with (a) 0.3% (w/v) porcine bile, (b) 3 mM TDCA or (c) 3 mM GDCA. Deconjugation was observed as an opaque precipitate surrounding the colonies.
  • HPLC High Performance Liquid Chromatography
  • Lactobacillus salivarius AH102, AH103, AH105, AH109 and AH110 were capable of growth (bile acid resistance) on three sources of bile used. It was observed that resistance to bovine bile was much higher than to porcine bile. Each of the Lactobacillus strains tested was resistant to concentrations up to and including 5.0% bovine bile (data not shown).
  • each of the Lactobacillus strains when analysed specifically for its resistance to individual bile acids, grew well in the presence of taurine conjugated bile acids. Isolates from each of Lactobacillus strain grew to confluence on agar medium containing up to and including 5 mM of taurine conjugates TCA, TDCA and TCDCA. Of the glycine conjugates tested, GCDCA was the most inhibitory. GDCA was less inhibitory and GCA was the least inhibitory of the three glycine conjugates. Each of the Lactobacillus strains grew on agar medium supplemented with 5 mM GCA. This is shown in Table 8 below.
  • Indicators used in the initial screening were L. innocua, L. fermentum KLD, P. flourescens and E. coli V157. Briefly, the lactobacilli (MRS) were incubated for 12-16 h and 36-48 h, respectively. Ten-fold serial dilutions were spread-plated (100 ⁇ l ) onto MRS/TPY agar medium. After overnight incubation, plates with distinct colonies were overlayed with the indicator bacterium. The indicator lawn was prepared by inoculating a molten overlay with 2% (v/v) of an overnight indicator culture which was poured over the surface of the inoculated MRS plates. The plates were re-incubated overnight under conditions suitable for growth of the indicator bacterium. Indicator cultures with inhibition zones greater than 1 mm in radius were considered sensitive to the test bacterium.
  • Lactobacillus salivarius AH102, AH103, AH105, AH109 and AH110 were screened for inhibitory activity using Ls. innocua, L. fermentum KLD, P. fluorescens and E. coli as indicator microorganisms. When the test strains were inoculated on unbuffered MRS, inhibition of the four indicators was observed. Zones ranging in size from 1 mm to 5 mm were measured. Inhibition of Ls. innocua by each of the lactobacilli produced the largest zones.
  • the adhesion of the probiotic strains was carried out using a modified version of a previously described method (22).
  • the monolayers of HT-29 and Caco-2 cells were prepared on sterile 22 mm 2 glass coverslips, which were placed in Corning tissue culture dishes, at a concentration of 4 ⁇ 10 4 cells/ml. Cells were fed fresh medium every 2 days. After ⁇ 10 days, and differentiation of the monolayer had occurred, the monolayers were washed twice with Phosphate Buffered Saline (PBS).
  • Antibiotic-free DMEM (2 ml) and 2 ml of ⁇ 18 h Lb. suspension containing ⁇ 10 9 cfu/ml were added to each dish and cells were incubated for 2 h at 37° C.
  • AH102, AH103 and AH105 stimulated production of IFN ⁇ from PBMCs (FIG. 2).
  • AH102, AH105, AH109 and AH110 co-incubation significantly upregulated IL-12 production by PBMCs (FIG. 4). AH103 had no significant effect on IL-12 production.
  • the appropriate in vitro model with physiological relevance to the intestinal tract is a culture system incorporating epithelial cells, T cells, B cells, monocytes and the bacterial strains.
  • human Caco-2 epithelial cells were seeded at 5 ⁇ 10 5 cells/ml on the apical surface of 25 mm transwell inserts with a pore size of 3 ⁇ m (Costar). These cells were cultured for four weeks in RPMI 1640, supplemented with 10% foetal calf serum, glutamine, penicillin and streptomycin, at 37° C. in a 5% CO 2 environment. Culture media was changed every 3 days.
  • PBMCs peripheral blood mononuclear cells
  • TNF ⁇ and IL-8 extracellular cytokine levels were measured using standard ELISA kits (R&D Systems). TNF ⁇ levels and IL-8 levels were measured, in duplicate, using PBMCs from 3 healthy volunteers.
  • TNF ⁇ and IL-8 cytokine levels were examined by ELISAs (FIG. 6).
  • AH103 significantly reduced the level of IL-8 released by these cells.
  • AH110 reduced the levels of TNF ⁇ and IL-8 released by these cells.
  • the human immune system plays a significant role in the aetiology and pathology of a vast range of human diseases. Hyper and hypo-immune responsiveness results in, or is a component of, the majority of disease states.
  • One family of biological entities, termed cytokines, are particularly important to the control of immune processes. Pertubances of these delicate cytokine networks are being increasingly associated with many diseases.
  • diseases include but are not limited to inflammatory disorders, immunodeficiency, inflammatory bowel disease, irritable bowel syndrome, cancer (particularly those of the gastrointestinal and immune systems), diarrhoeal disease, antibiotic associated diarrhoea, paediatric diarrhoea, appendicitis, autoimmune disorders, multiple sclerosis, Alzheimer's disease, rheumatoid arthritis, coeliac disease, diabetes mellitus, organ transplantation, bacterial infections, viral infections, fungal infections, periodontal disease, urogenital disease, sexually transmitted disease, HIV infection, HIV replication, HIV associated diarrhoea, surgical associated trauma, surgical-induced metastatic disease, sepsis, weight loss, anorexia, fever control, cachexia, wound healing, ulcers, gut barrier function, allergy, asthma, respiratory disorders, circulatory disorders, coronary heart disease, anaemia, disorders of the blood coagulation system, renal disease, disorders of the central nervous system, hepatic disease, ischaemia, nutritional disorders, osteop
  • cytokine production is specific for each of the probiotic strains examined.
  • specific probiotic strains may be selected for normalising an exclusive cytokine imbalance particular for a specific disease type.
  • Customisation of disease specific therapies can be accomplished using a selection of the probiotic strains listed above.
  • the enteric flora is important to the development and proper function of the intestinal immune system. In the absence of an enteric flora, the intestinal immune system is underdeveloped, as demonstrated in germ free animal models, and certain functional parameters are diminished, such as macrophage phagocytic ability and immunoglobulin production (23). The importance of the gut flora in stimulating nondamaging immune responses is becoming more evident. The increase in incidence and severity of allergies in the western world has been linked with an increase in hygiene and sanitation, concomitant with a decrease in the number and range of infectious challenges encountered by the host. This lack of immune stimulation may allow the host to react to non-pathogenic, but antigenic, agents resulting in allergy or autoimmunity. Deliberate consumption of a series of non-pathogenic immunomodulatory bacteria would provide the host with the necessary and appropriate educational stimuli for proper development and control of immune function.
  • Inflammation is the term used to describe the local accumulation of fluid, plasma proteins and white blood cells at a site that has sustained physical damage, infection or where there is an ongoing immune response. Control of the inflammatory response is exerted on a number of levels (24).
  • the controlling factors include cytokines, hormones (e.g. hydrocortisone), prostaglandins, reactive intermediates and leukotrienes.
  • Cytokines are low molecular weight biologically active proteins that are involved in the generation and control of immunological and inflammatory responses, while also regulating development, tissue repair and haematopoiesis. They provide a means of communication between leukocytes themselves and also with other cell types. Most cytokines are pleiotrophic and express multiple biologically overlapping activities.
  • Cytokine cascades and networks control the inflammatory response rather than the action of a particular cytokine on a particular cell type (25). Waning of the inflammatory response results in lower concentrations of the appropriate activating signals and other inflammatory mediators leading to the cessation of the inflammatory response.
  • TNF ⁇ is a pivotal proinflammatory cytokine as it initiates a cascade of cytokines and biological effects resulting in the inflammatory state. Therefore, agents which inhibit TNF ⁇ are currently being used for the treatment of inflammatory diseases, e.g. infliximab.
  • Pro-inflammatory cytokines are thought to play a major role in the pathogenesis of many inflammatory diseases, including inflammatory bowel disease (IBD).
  • IBD inflammatory bowel disease
  • Current therapies for treating IBD are aimed at reducing the levels of these pro-inflammatory cytokines, including IL-8 and TNF ⁇ .
  • Such therapies may also play a significant role in the treatment of systemic inflammatory diseases such as rheumatoid arthritis.
  • IBS Irritable bowel syndrome
  • strains of the invention have unique properties with regard to cytokine modulation and microbial antagonism profiles, it should be expected that specific strains can be chosen for use in specific disease states based on these properties. It also should be anticipated that combinations of strains from this panel with appropriate cytokine modulating properties and anti-microbial properties will enhance therapeutic efficacy.
  • strains of the present invention may have potential application in the treatment of a range of inflammatory diseases, particularly if used in combination with other anti-inflammatory therapies, such as non-steroid anti-inflammatory drugs (NSAIDs) or Infliximab.
  • NSAIDs non-steroid anti-inflammatory drugs
  • Infliximab Infliximab
  • the inflammatory response may have significant roles to play in the above mechanisms, thus contributing to the decline of the host and progression of the tumour.
  • intestinal bacteria can produce, from dietary compounds, substances with genotoxic, carcinogenic and tumour-promoting activity and gut bacteria can activate pro-carcinogens to DNA reactive agents (28).
  • species of Lactobacillus have low activities of xenobiotic metabolizing enzymes compared to other populations within the gut such as bacteroides, eubacteria and clostridia. Therefore, increasing the number of Lactobacillus bacteria in the gut could beneficially modify the levels of these enzymes.
  • TTFC tetanus toxin fragment C
  • probiotic organisms are accomplished by the ingestion of the micro-organism in a suitable carrier. It would be advantageous to provide a medium that would promote the growth of these probiotic strains in the large bowel.
  • the addition of one or more oligosaccharides, polysaccharides, or other prebiotics enhances the growth of lactic acid bacteria in the gastrointestinal tract.
  • Prebiotics refers to any non-viable food component that is specifically fermented in the colon by indigenous bacteria thought to be of positive value, e.g. bifidobacteria, lactobacilli. Types of prebiotics may include those that contain fructose, xylose, soya, galactose, glucose and mannose.
  • the combined administration of a probiotic strain with one or more prebiotic compounds may enhance the growth of the administered probiotic in vivo resulting in a more pronounced health benefit, and is termed synbiotic.
  • the probiotic strains may be administered prophylactically or as a method of treatment either on its own or with other probiotic and/or prebiotic materials as described above.
  • the bacteria may be used as part of a prophylactic or treatment regime using other active materials such as those used for treating inflammation or other disorders especially those with an immunological involvement.
  • Such combinations may be administered in a single formulation or as separate formulations administered at the same or different times and using the same or different routes of administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
US10/205,318 2001-07-26 2002-07-26 Probiotic lactobacillus salivarius strains Abandoned US20030091549A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/105,590 US7390519B2 (en) 2001-07-26 2005-04-14 Probiotic Lactobacillus salivarius strains

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
IE20010701 2001-07-26
IE2001/0707 2001-07-26
IE20010708 2001-07-26
IE2001/0708 2001-07-26
IE2001/0701 2001-07-26
IE20010707 2001-07-26
IE2001/0705 2001-07-26
IE20010702 2001-07-26
IE20010705 2001-07-26
IE2001/0702 2001-07-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/105,590 Continuation US7390519B2 (en) 2001-07-26 2005-04-14 Probiotic Lactobacillus salivarius strains

Publications (1)

Publication Number Publication Date
US20030091549A1 true US20030091549A1 (en) 2003-05-15

Family

ID=27517572

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/205,318 Abandoned US20030091549A1 (en) 2001-07-26 2002-07-26 Probiotic lactobacillus salivarius strains
US11/105,590 Expired - Fee Related US7390519B2 (en) 2001-07-26 2005-04-14 Probiotic Lactobacillus salivarius strains

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/105,590 Expired - Fee Related US7390519B2 (en) 2001-07-26 2005-04-14 Probiotic Lactobacillus salivarius strains

Country Status (16)

Country Link
US (2) US20030091549A1 (enrdf_load_stackoverflow)
EP (1) EP1409645B1 (enrdf_load_stackoverflow)
JP (1) JP4415164B2 (enrdf_load_stackoverflow)
CN (1) CN1639317B (enrdf_load_stackoverflow)
AT (1) ATE439426T1 (enrdf_load_stackoverflow)
AU (1) AU2002329007C1 (enrdf_load_stackoverflow)
BR (1) BR0211441A (enrdf_load_stackoverflow)
CA (1) CA2454804C (enrdf_load_stackoverflow)
DE (1) DE60233326D1 (enrdf_load_stackoverflow)
DK (1) DK1409645T3 (enrdf_load_stackoverflow)
IL (2) IL160049A0 (enrdf_load_stackoverflow)
IN (1) IN2004KN00092A (enrdf_load_stackoverflow)
MX (1) MXPA04000808A (enrdf_load_stackoverflow)
NZ (1) NZ543584A (enrdf_load_stackoverflow)
PE (1) PE20030274A1 (enrdf_load_stackoverflow)
WO (1) WO2003010298A1 (enrdf_load_stackoverflow)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080206211A1 (en) * 2007-02-26 2008-08-28 L'oreal Composition containing a cell culture medium
US20080206213A1 (en) * 2007-02-28 2008-08-28 Bristol-Myers Squibb Company Method for reducing or preventing systemic inflammation
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20120171193A1 (en) * 2007-07-31 2012-07-05 New York University Diagnostic and Treatment Methods for Characterizing Bacterial Microbiota in Skin Conditions
US9011909B2 (en) 2010-09-03 2015-04-21 Wisconsin Pharmacal Company, Llc Prebiotic suppositories
US11406674B2 (en) 2018-01-26 2022-08-09 Probisearch, S.L.U. Composition comprising new Lactobacillus salivarius strains and method for the prevention and treatment of otitis and upper respiratory infections
CN115725456A (zh) * 2022-10-11 2023-03-03 四川大学 一种唾液乳杆菌及其应用

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
EP1608383A1 (en) * 2003-03-31 2005-12-28 Alimentary Health Limited A formulation comprising a bacterial strain
US20040197304A1 (en) 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
WO2004104175A2 (en) * 2003-05-14 2004-12-02 University Of Georgia Research Foundation, Inc. Probiotic bacteria and methods
WO2005030230A1 (en) * 2003-09-30 2005-04-07 Probiomics Limited Compositions and methods for treatment or prevention of psoriasis and related disorders
CN100421676C (zh) 2003-12-17 2008-10-01 纽迪西亚公司 乳酸产生细菌和肺功能
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) * 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
AU2006253006B8 (en) 2005-05-31 2011-09-15 Alimentary Health Ltd Feline probiotic Lactobacilli
JP4938006B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティク・ビフィドバクテリア
WO2008079009A1 (en) * 2006-12-22 2008-07-03 Campina Nederland Holding B.V. Immunomodulating probiotic lactic acid bacteria
BRPI0808391A2 (pt) 2007-02-01 2014-07-08 Lams Company Método para diminuir a inflamação e o estresse em um mamífero, mediante o uso de antimetabólitos de glicose, abacate ou extratos de abacate.
RU2394559C2 (ru) * 2008-01-28 2010-07-20 Федеральное государственное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии имени Г.Н. Габричевского Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" (ФГУН МНИИЭМ им. Г.Н. Габричевского Роспотребнадзора") Способ установления неспецифического противоинфекционного действия иммуномодулирующего иммунобиологического препарата
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
RU2500412C2 (ru) * 2008-09-04 2013-12-10 Ом Фарма ИММУНОМОДУЛИРУЮЩИЕ ЭКСТРАКТЫ ИЗ БАКТЕРИЙ Lactobacillus И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
US20100055082A1 (en) * 2008-09-04 2010-03-04 Jacques Alain Bauer Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof
WO2010096550A2 (en) 2009-02-18 2010-08-26 University Of Florida Research Foundation, Inc. Lactobacillus supplement for alleviating type 1 diabetes
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8372392B2 (en) 2009-12-23 2013-02-12 Lytone Enterprise, Inc. Lactobacillus paracasei strain LT12 as immunity regulatory agent
US20110293710A1 (en) * 2010-02-02 2011-12-01 Delphine Saulnier Immunomodulatory properties of lactobacillus strains
CN102618452B (zh) * 2011-02-01 2014-06-25 任发政 唾液乳杆菌及其代谢物的制备方法和组合物以及应用
CN103555604B (zh) * 2013-03-25 2014-09-17 浙江大学 能够抑制白色念珠菌生长的唾液乳酸杆菌及其分离方法
CN106414708A (zh) 2014-01-24 2017-02-15 宝洁公司 包含含有微生物的纤维元件的纤维网及其制备方法
US20150209468A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Hygiene article containing microorganism
US20150209392A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Filaments Comprising a Microorganism and Method for Making Same
JP6485843B2 (ja) * 2014-09-30 2019-03-20 ビージーアイ シェンチェン 関節リウマチのバイオマーカー及びその使用
US20160354507A1 (en) 2015-06-07 2016-12-08 The Procter & Gamble Company Article of commerce containing absorbent article
GB201514302D0 (en) * 2015-07-16 2015-09-23 Dupont Nutrition Biosci Aps Lactobacilli for treating cardiac dysfunction
US20170020750A1 (en) 2015-07-23 2017-01-26 The Procter & Gamble Company Patch containing microorganism
CN108135948B (zh) * 2015-08-25 2022-04-12 免疫生物技术医疗瑞典公司 用于治疗和预防肠感染和炎症的组合物和方法
MA45334A (fr) 2016-03-24 2019-01-30 Probiotical Spa Composition bactérienne d'acide lactique pour le traitement d'infections vaginales bactériennes par gardnerella vaginalis et, éventuellement, d'infections fongiques concurrentes
KR101873899B1 (ko) * 2016-08-09 2018-07-03 씨제이제일제당(주) 락토바실러스 살리바리우스 cjls1511, 상기 균 또는 이의 사균체를 포함하는 동물 사료 첨가제 조성물, 및 상기 사균체의 제조 방법
TWI598103B (zh) * 2016-08-22 2017-09-11 景岳生物科技股份有限公司 改善困難梭狀桿菌感染症狀的發酵乳酸桿菌ｇｍｎｌ－２９６組合物及方法
PL3412766T3 (pl) * 2017-06-06 2021-07-19 Casen Recordati, S.L. Szczep lactobacillus salivarius, zawierająca go kompozycja i jego zastosowania
IT201700068009A1 (it) * 2017-06-19 2018-12-19 Probiotical Spa Composizione comprendente ceppi di batteri appartenenti alla specie Lactobacillus salivarius per il trattamento del morbo di Parkinson
KR101978455B1 (ko) * 2018-01-03 2019-05-14 대한민국(농촌진흥청장) 락토바실러스 살리바리우스 DJ-sa-01 균주 및 이를 포함하는 면역 증강용 조성물
CN109486700A (zh) * 2018-08-31 2019-03-19 石家庄君乐宝乳业有限公司 副干酪乳杆菌n1115预防结肠炎的应用及相应的益生菌粉、应用
TWI748395B (zh) * 2020-03-31 2021-12-01 豐華生物科技股份有限公司 緩解過敏以及提升運動表現之組合物及其用途
CN113337440B (zh) * 2021-06-21 2023-02-21 美益添生物医药(武汉)有限公司 一株唾液乳杆菌mg-587及其应用
CN116200313B (zh) * 2023-04-07 2023-11-21 西南科技大学 一株唾液乳杆菌及其应用
CN117089505B (zh) * 2023-10-20 2024-03-19 杭州微致生物科技有限公司 一种副干酪乳杆菌vb306及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132710A (en) * 1997-03-17 2000-10-17 Probiotix, Inc. Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1382467A1 (ru) * 1986-09-03 1988-03-23 Ереванское Производственное Объединение "Молоко" Способ производства сыра
RU2000116C1 (ru) * 1991-07-22 1993-09-07 Институт Микробиологии И Вирусологии Им.Д.К.Заболотного Способ получени пробиотика дл животноводства, преимущественно птицеводства
JP3220699B2 (ja) * 1992-03-06 2001-10-22 株式会社日清製粉グループ本社 家禽用発育促進剤
RU2055827C1 (ru) * 1992-12-30 1996-03-10 Акционерное общество "Биотехнология" Консорциум бактерий (lactobacillus salivarius var.salivarius, streptococcus thermophilus, streptococcus bovis) для активации прорастания семян
ATE496989T1 (de) * 1997-02-11 2011-02-15 Entpr Ie Trd As Bioresearch Ie Probiotische stämme des lactobacillus salivarius und daraus hergestellte antimikrobielle mittel
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
DE19945746C1 (de) * 1999-09-24 2001-04-19 Theodor Backs Gmbh Mittel zur Behandlung von Ziervogelkrankheiten
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
KR100585392B1 (ko) * 2002-01-24 2006-05-30 주식회사 프로바이오닉 돼지 전염성위장염 (TGE) 코로나바이러스 및 유해 미생물 억제 활성을 갖는 신규 락토바실러스 살리바리우스 Probio-37 및 이를 함유하는 생균활성제
EP1571915B1 (en) * 2002-10-30 2010-12-15 MacQuarrie, Reg Edible dissolving gelatin strips

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132710A (en) * 1997-03-17 2000-10-17 Probiotix, Inc. Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20080166719A1 (en) * 2006-08-15 2008-07-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US8463553B2 (en) 2006-08-15 2013-06-11 Nestec S.A. Methods for diagnosing irritable bowel syndrome
US20080206211A1 (en) * 2007-02-26 2008-08-28 L'oreal Composition containing a cell culture medium
US9408819B2 (en) 2007-02-28 2016-08-09 Mead Johnson Nutrition Company Method for reducing or preventing systemic inflammation
US20080206213A1 (en) * 2007-02-28 2008-08-28 Bristol-Myers Squibb Company Method for reducing or preventing systemic inflammation
US20120171193A1 (en) * 2007-07-31 2012-07-05 New York University Diagnostic and Treatment Methods for Characterizing Bacterial Microbiota in Skin Conditions
US8529892B2 (en) * 2007-07-31 2013-09-10 New York University Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions
US9011909B2 (en) 2010-09-03 2015-04-21 Wisconsin Pharmacal Company, Llc Prebiotic suppositories
US11406674B2 (en) 2018-01-26 2022-08-09 Probisearch, S.L.U. Composition comprising new Lactobacillus salivarius strains and method for the prevention and treatment of otitis and upper respiratory infections
US11903983B2 (en) 2018-01-26 2024-02-20 Probisearch, S.L.U. Composition comprising new Lactobacillus salivarius strains and method for the prevention and treatment of otitis and upper respiratory infections
CN115725456A (zh) * 2022-10-11 2023-03-03 四川大学 一种唾液乳杆菌及其应用

Also Published As

Publication number Publication date
JP2005506063A (ja) 2005-03-03
AU2002329007B2 (en) 2008-03-06
BR0211441A (pt) 2004-11-09
DE60233326D1 (de) 2009-09-24
IL160049A0 (en) 2004-06-20
MXPA04000808A (es) 2004-05-21
NZ543584A (en) 2008-04-30
CN1639317A (zh) 2005-07-13
EP1409645B1 (en) 2009-08-12
US7390519B2 (en) 2008-06-24
CN1639317B (zh) 2011-04-27
PE20030274A1 (es) 2003-05-08
ATE439426T1 (de) 2009-08-15
EP1409645A1 (en) 2004-04-21
US20060078547A1 (en) 2006-04-13
AU2002329007C1 (en) 2008-10-30
IL160049A (en) 2009-12-24
DK1409645T3 (da) 2009-12-14
CA2454804A1 (en) 2003-02-06
CA2454804C (en) 2011-02-01
IN2004KN00092A (enrdf_load_stackoverflow) 2006-03-03
WO2003010298A1 (en) 2003-02-06
JP4415164B2 (ja) 2010-02-17

Similar Documents

Publication Publication Date Title
US7390519B2 (en) Probiotic Lactobacillus salivarius strains
US20030113306A1 (en) Probiotic lactobacillus casei strains
US20060121015A1 (en) Probiotic bifidobacterium strains
US20220169976A1 (en) Probiotic bifidobacterium strain
AU2002329007A1 (en) "Probiotic Lactobacillus salivarius strains"
US20110020400A1 (en) Probiotic bifidobacterium strains
RU2302458C2 (ru) Пробиотический штамм lactobacillus salivarius (варианты), пробиотический препарат на их основе и способ лечения или предупреждения с использованием штаммов lactobacillus salivarius
AU2002328131A1 (en) Probiotic lactobacillus casei strains
IE20020624A1 (en) Probiotic Lactobacillus casei strains
ZA200400557B (en) Probiotic lactobacillus casei strains.
IE20020620A1 (en) Probiotic Lactobacillus salivarius strains
ZA200400556B (en) Probiotic lactobacillus salivarius strains.
ZA200400555B (en) Probiotic bifidobacterium strains.
IE20020626A1 (en) Probiotic Bifidobacterium strains

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALIMENTARY HEALTH LIMITED, IRELAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COLLINS, JOHN KEVIN;O'SULLIVAN, GERALD CHRISTOPHER;O'MAHONY, LIAM;AND OTHERS;REEL/FRAME:013155/0941

Effective date: 20020719

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION